Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
mTOR inhibitor

Temsirolimus (Specialist drug)

Brand names: Torisel

Temsirolimus is an intravenous mTOR inhibitor used in the treatment of advanced renal cell carcinoma and mantle cell lymphoma. It is a specialist drug given under oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the mTOR kinase, blocking signalling pathways that drive cell-cycle progression, angiogenesis and tumour growth.

Prescribing in practice

  • Hypersensitivity and infusion reactions can occur, so antihistamine premedication is given and infusions are administered with close monitoring.
  • It commonly causes metabolic disturbances including hyperglycaemia, hyperlipidaemia and an increased infection risk, alongside non-infectious pneumonitis.
  • It is metabolised via CYP3A4, so strong inhibitors and inducers and concurrent live vaccines should be avoided.

Monitoring

Monitor blood glucose, lipids, full blood count, renal and liver function, and watch for respiratory symptoms suggestive of pneumonitis.

Counselling the patient

  • Report new or worsening breathlessness, cough or fever, which need prompt assessment.
  • Attend for blood tests to check your blood sugar, cholesterol and blood counts.
  • Tell your team about all other medicines, as some interact with this treatment.

Evidence & guidelines

Temsirolimus improved overall survival versus interferon in poor-prognosis advanced renal cell carcinoma in a pivotal randomised trial.

Reference: NICE TA178; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways